Key result
MDM2 and CDK4 immunostainings demonstrated high sensitivity (97% and 92%) and specificity (83% and 95%) for identifying ALT-WDLPS and DDLPS among other soft tissue tumors.
Why the study?
Are MDM2 and CDK4 immunostainings useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes?
Observational (n=559)
Are MDM2 and CDK4 immunostainings useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes?
MDM2 and CDK4 immunostainings are highly sensitive and specific adjuncts for differentiating ALT-WDLPS and DDLPS from benign adipose tumors and poorly differentiated sarcomas.
No takes yet. Share an insight, caveat, or question.
Supports MDM2/CDK4 IHC as diagnostic adjuncts; leaves open prospective validation before routine adoption.
Binh et al. (2005) conducted an observational in Soft tissue tumors (ALT-WDLPS, DDLPS, benign adipose tumors, and other sarcomas) (n=559). MDM2 and CDK4 immunostaining vs. Benign adipose tumors and poorly differentiated sarcomas was evaluated on Sensitivity and specificity of MDM2 and CDK4 immunostainings in identifying ALT-WDLPS/DDLPS. MDM2 and CDK4 immunostainings demonstrated high sensitivity (97% and 92%) and specificity (83% and 95%) for identifying ALT-WDLPS and DDLPS among other soft tissue tumors.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: